Rapid‐acting insulin analogues are widely used in insulin pump‐treated type 1 diabetes and closed‐loop insulin delivery systems.1 However, little is known about the association between its pharmacodynamics, and demographic factors and glycaemic outcomes during closed‐loop insulin delivery and sensor‐augmented pump therapy. The gene discussed is INS; the disease is type 1 diabetes mellitus.